Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs

Andreas Robert Rudolf Weiss, Marc Hendrik Dahlke, Andreas Robert Rudolf Weiss, Marc Hendrik Dahlke

Abstract

Expectations on mesenchymal stem cell (MSC) treatment are high, especially in the fields of sepsis, transplant medicine, and autoimmune diseases. Various pre-clinical studies have been conducted with encouraging results, although the mechanisms of action behind the observed immunomodulatory capacity of mesenchymal stem cells have not been fully understood. Previous studies have demonstrated that the immunomodulatory effect of MSCs is communicated via MSC-secreted cytokines and has been proven to rely on the local microenvironment as some of the observed effects depend on a pre-treatment of MSCs with inflammatory cytokines. Nonetheless, recent findings indicate that the cytokine-mediated effects are only one part of the equation as apoptotic, metabolically inactivated, or even fragmented MSCs have been shown to possess an immunomodulatory potential as well. Both cytokine-dependent and cytokine-independent mechanisms suggest a key role for regulatory T cells and monocytes in the overall pattern, but the principle as to why viable and non-viable MSCs have similar immunomodulatory capacities remains elusive. Here we review the current knowledge on cellular and molecular mechanisms involved in MSC-mediated immunomodulation and focus on the viability of MSCs, as there is still uncertainty concerning the tumorigenic potential of living MSCs.

Keywords: HI-MSC; apoptosis; immunogenicity; immunomodulation; mesenchymal stem cell (MSC); monocytes; regulatory T cells; tumor induction.

Figures

Figure 1
Figure 1
(A) Proposed interaction of MSCs with host immune cells. (B) Proposed pathway of MSC-mediated anti-inflammation via phagocytosis of MSCs [in accordance with De Witte et al. (31) and Braza et al. (53)].

References

    1. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. (2008) 371:1579–86. 10.1016/S0140-6736(08)60690-X
    1. Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, et al. . A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol. (2014) 12:64–71. 10.1016/j.cgh.2013.06.021
    1. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. (2009) 136:978–89. 10.1053/j.gastro.2008.11.041
    1. Reinders ME, de Fijter JW, Roelofs H, Bajema IM, de Vries DK, Schaapherder AF, et al. . Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med. (2013) 2:107–11. 10.5966/sctm.2012-0114
    1. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. . Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. (2002) 30:42–8. 10.1016/S0301-472X(01)00769-X
    1. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. . Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. (2009) 15:42–9. 10.1038/nm.1905
    1. Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, et al. . Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. (2013) 60:347–57. 10.1507/endocrj.EJ12-0343
    1. Wu Y, Hoogduijn MJ, Baan CC, Korevaar SS, de Kuiper R, Yan L, et al. . Adipose Tissue-derived mesenchymal stem cells have a heterogenic cytokine secretion profile. Stem Cells Int. (2017) 2017:4960831. 10.1155/2017/4960831
    1. Nasef A, Mathieu N, Chapel A, Frick J, Francois S, Mazurier C, et al. . Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation. (2007) 84:231–7. 10.1097/01.tp.0000267918.07906.08
    1. Deng Y, Zhang Y, Ye L, Zhang T, Cheng J, Chen G, et al. . Umbilical cord-derived mesenchymal stem cells instruct monocytes towards an IL10-producing phenotype by secreting IL6 and HGF. Sci Rep. (2016) 6:37566. 10.1038/srep37566
    1. De Witte SFH, Peters FS, Merino A, Korevaar SS, Van Meurs JBJ, O'Flynn L, et al. Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansion. Cytotherapy. (2018) 20:919–29. 10.1016/j.jcyt.2018.05.005
    1. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol. (2006) 7:14. 10.1186/1471-2121-7-14
    1. Schellenberg A, Lin Q, Schuler H, Koch CM, Joussen S, Denecke B, et al. . Replicative senescence of mesenchymal stem cells causes DNA-methylation changes which correlate with repressive histone marks. Aging. (2011) 3:873–88. 10.18632/aging.100391
    1. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells. (2004) 22:675–82. 10.1634/stemcells.22-5-675
    1. de Witte SFH, Lambert EE, Merino A, Strini T, Douben HJCW, O'Flynn L, et al. Aging of bone marrow- and umbilical cord-derived mesenchymal stromal cells during expansion. Cytotherapy. (2017) 19:798–807. 10.1016/j.jcyt.2017.03.071
    1. Yin JQ, Zhu J, Ankrum JA. Manufacturing of primed mesenchymal stromal cells for therapy. Nat Biomed Eng. (2019) 28:90–104. 10.1038/s41551-018-0325-8
    1. Elahi KC, Klein G, Avci-Adali M, Sievert KD, MacNeil S, Aicher WK. Human Mesenchymal stromal cells from different sources diverge in their expression of cell surface proteins and display distinct differentiation patterns. Stem Cells Int. (2016) 2016:5646384. 10.1155/2016/5646384
    1. Hass R, Kasper C, Bohm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. (2011) 9:12. 10.1186/1478-811X-9-12
    1. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. (2006) 119(Pt 11):2204–13. 10.1242/jcs.02932
    1. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. . Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. (2005) 65:3307–18. 10.1158/0008-5472.CAN-04-1874
    1. Chang CL, Leu S, Sung HC, Zhen YY, Cho CL, Chen A, et al. . Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in rat sepsis syndrome induced by cecal puncture and ligation. J Transl Med. (2012) 10:244. 10.1186/1479-5876-10-244
    1. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. (2007) 179:1855–63. 10.4049/jimmunol.179.3.1855
    1. Munoz MF, Arguelles S, Guzman-Chozas M, Guillen-Sanz R, Franco JM, Pintor-Toro JA, et al. . Cell tracking, survival, and differentiation capacity of adipose-derived stem cells after engraftment in rat tissue. J Cell Physiol. (2018) 233:6317–28. 10.1002/jcp.26439
    1. Avritscher R, Abdelsalam ME, Javadi S, Ensor J, Wallace MJ, Alt E, et al. . Percutaneous intraportal application of adipose tissue-derived mesenchymal stem cells using a balloon occlusion catheter in a porcine model of liver fibrosis. J Vasc Interv Radiol. (2013) 24:1871–8. 10.1016/j.jvir.2013.08.022
    1. Moll G, Geissler S, Catar R, Ignatowicz L, Hoogduijn MJ, Strunk D, et al. . Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy? Adv Exp Med Biol. (2016) 951:77–98. 10.1007/978-3-319-45457-3_7
    1. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. (2014) 15:1009–16. 10.1038/ni.3002
    1. Luk F, Carreras-Planella L, Korevaar SS, de Witte SFH, Borras FE, Betjes MGH, et al. . Inflammatory conditions dictate the effect of mesenchymal stem or stromal cells on B cell function. Front Immunol. (2017) 8:1042. 10.3389/fimmu.2017.01042
    1. de Witte SFH, Merino AM, Franquesa M, Strini T, van Zoggel JAA, Korevaar SS, et al. Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. Stem Cell Res Ther. (2017) 8:140 10.1186/s13287-017-0590-6
    1. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. (2012) 3:297 10.3389/fimmu.2012.00297
    1. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, et al. . Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. (2009) 18:683–91. 10.1089/scd.2008.0253
    1. de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of msc by monocytic cells. Stem Cells. (2018) 36:602–15. 10.1002/stem.2779
    1. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. (2010) 90:1312–20. 10.1097/TP.0b013e3181fed001
    1. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. (2008) 111:1327–33. 10.1182/blood-2007-02-074997
    1. Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, et al. . Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol. (2008) 20:55–60. 10.1016/j.trim.2008.08.004
    1. Obermajer N, Popp FC, Soeder Y, Haarer J, Geissler EK, Schlitt HJ, et al. . Conversion of Th17 into IL-17A(neg) regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy. J Immunol. (2014) 193:4988–99. 10.4049/jimmunol.1401776
    1. Luz-Crawford P, Djouad F, Toupet K, Bony C, Franquesa M, Hoogduijn MJ, et al. . Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells. (2016) 34:483–92. 10.1002/stem.2254
    1. Eggenhofer E, Popp FC, Mendicino M, Silber P, Van't Hof W, Renner P, et al. . Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression. Stem Cells Transl Med. (2013) 2:595–606. 10.5966/sctm.2012-0166
    1. Riquelme P, Haarer J, Kammler A, Walter L, Tomiuk S, Ahrens N, et al. . TIGIT(+) iTregs elicited by human regulatory macrophages control T cell immunity. Nat Commun. (2018) 9:2858. 10.1038/s41467-018-05167-8
    1. Goncalves FDC, Luk F, Korevaar SS, Bouzid R, Paz AH, Lopez-Iglesias C, et al. . Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes. Sci Rep. (2017) 7:12100. 10.1038/s41598-017-12121-z
    1. Melief SM, Geutskens SB, Fibbe WE, Roelofs H. Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica. (2013) 98:888–95. 10.3324/haematol.2012.078055
    1. Luk F, de Witte SF, Korevaar SS, Roemeling-van Rhijn M, Franquesa M, Strini T, et al. . Inactivated mesenchymal stem cells maintain immunomodulatory capacity. Stem Cells Dev. (2016) 25:1342–54. 10.1089/scd.2016.0068
    1. Zheng G, Huang R, Qiu G, Ge M, Wang J, Shu Q, et al. . Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis. Cell Tissue Res. (2018) 374:1–15. 10.1007/s00441-018-2871-5
    1. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. (2007) 83:71–6. 10.1097/01.tp.0000244572.24780.54
    1. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. . Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. (2005) 105:4120–6. 10.1182/blood-2004-02-0586
    1. Melief SM, Schrama E, Brugman MH, Tiemessen MM, Hoogduijn MJ, Fibbe WE, et al. . Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells. (2013) 31:1980–91. 10.1002/stem.1432
    1. Ko JH, Lee HJ, Jeong HJ, Kim MK, Wee WR, Yoon SO, et al. . Mesenchymal stem/stromal cells precondition lung monocytes/macrophages to produce tolerance against allo- and autoimmunity in the eye. Proc Natl Acad Sci USA. (2016) 113:158–63. 10.1073/pnas.1522905113
    1. Schmidt A, Zhang XM, Joshi RN, Iqbal S, Wahlund C, Gabrielsson S, et al. . Human macrophages induce CD4(+)Foxp3(+) regulatory T cells via binding and re-release of TGF-β. Immunol Cell Biol. (2016) 94:747–62. 10.1038/icb.2016.34
    1. Chang Y, de Nadai P, Azzaoui I, Morales O, Delhem N, Vorng H, et al. The chemokine CCL18 generates adaptive regulatory T cells from memory CD4+ T cells of healthy but not allergic subjects. FASEB J. (2010) 24:5063–72. 10.1096/fj.10-162560
    1. Azzaoui I, Yahia SA, Chang Y, Vorng H, Morales O, Fan Y, et al. . CCL18 differentiates dendritic cells in tolerogenic cells able to prime regulatory T cells in healthy subjects. Blood. (2011) 118:3549–58. 10.1182/blood-2011-02-338780
    1. Eggenhofer E, Luk F, Dahlke MH, Hoogduijn MJ. The life and fate of mesenchymal stem cells. Front Immunol. (2014) 5:148. 10.3389/fimmu.2014.00148
    1. Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol. (1998) 160:1411–8.
    1. Vulcano M, Struyf S, Scapini P, Cassatella M, Bernasconi S, Bonecchi R, et al. . Unique regulation of CCL18 production by maturing dendritic cells. J Immunol. (2003) 170:3843–9. 10.4049/jimmunol.170.7.3843
    1. Braza F, Dirou S, Forest V, Sauzeau V, Hassoun D, Chesne J, et al. . Mesenchymal stem cells induce suppressive macrophages through phagocytosis in a mouse model of asthma. Stem Cells. (2016) 34:1836–45. 10.1002/stem.2344
    1. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett. (2008) 115:50–8. 10.1016/j.imlet.2007.10.002
    1. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. (2005) 105:1815–22. 10.1182/blood-2004-04-1559
    1. Liu X, Ren S, Ge C, Cheng K, Zenke M, Keating A, et al. . Sca-1+Lin-CD117- mesenchymal stem/stromal cells induce the generation of novel IRF8-controlled regulatory dendritic cells through Notch-RBP-J signaling. J Immunol. (2015) 194:4298–308. 10.4049/jimmunol.1402641
    1. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, et al. . Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. (2012) 302:L1003–13. 10.1152/ajplung.00180.2011
    1. Miteva K, Pappritz K, El-Shafeey M, Dong F, Ringe J, Tschope C, et al. . Mesenchymal stromal cells modulate monocytes trafficking in coxsackievirus b3-induced myocarditis. Stem Cells Transl Med. (2017) 6:1249–61. 10.1002/sctm.16-0353
    1. Eggenhofer E, Steinmann JF, Renner P, Slowik P, Piso P, Geissler EK, et al. . Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol. (2011) 24:157–63. 10.1016/j.trim.2010.12.002
    1. Gieseke F, Bohringer J, Bussolari R, Dominici M, Handgretinger R, Muller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood. (2010) 116:3770–9. 10.1182/blood-2010-02-270777
    1. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther. (2011) 2:34. 10.1186/scrt75
    1. Wang Q, Sun B, Wang D, Ji Y, Kong Q, Wang G, et al. . Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance. Scand J Immunol. (2008) 68:607–15. 10.1111/j.1365-3083.2008.02180.x
    1. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. . Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. (2009) 57:1192–203. 10.1002/glia.20841
    1. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, et al. . Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol. (2009) 183:993–1004. 10.4049/jimmunol.0900803
    1. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, MacIsaac KD, et al. . Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature. (2007) 445:931–5. 10.1038/nature05478
    1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. (1995) 155:1151–64.
    1. Khosravi M, Karimi MH, Hossein Aghdaie M, Kalani M, Naserian S, Bidmeshkipour A. Mesenchymal stem cells can induce regulatory T cells via modulating miR-126a but not miR-10a. Gene. (2017) 627:327–36. 10.1016/j.gene.2017.06.012
    1. Engela AU, Hoogduijn MJ, Boer K, Litjens NHR, Betjes MGH, Weimar W, et al. . Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA. Clin Exp Immunol. (2013) 173:343–54. 10.1111/cei.12120
    1. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. (2004) 103:4619–21. 10.1182/blood-2003-11-3909
    1. Cutler AJ, Limbani V, Girdlestone J, Navarrete CV. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol. (2010) 185:6617–23. 10.4049/jimmunol.1002239
    1. Davies LC, Heldring N, Kadri N, Le Blanc K. Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression. Stem Cells. (2017) 35:766–76. 10.1002/stem.2509
    1. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. . Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. (2005) 105:2214–9. 10.1182/blood-2004-07-2921
    1. Franquesa M, Mensah FK, Huizinga R, Strini T, Boon L, Lombardo E, et al. . Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells. (2015) 33:880–91. 10.1002/stem.1881
    1. Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity. (2015) 42:607–12. 10.1016/j.immuni.2015.04.005
    1. Carter NA, Vasconcellos R, Rosser EC, Tulone C, Munoz-Suano A, Kamanaka M, et al. . Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol. (2011) 186:5569–79. 10.4049/jimmunol.1100284
    1. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. . Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. (2007) 109:228–34. 10.1182/blood-2006-02-002246
    1. Chen HH, Lin KC, Wallace CG, Chen YT, Yang CC, Leu S, et al. . Additional benefit of combined therapy with melatonin and apoptotic adipose-derived mesenchymal stem cell against sepsis-induced kidney injury. J Pineal Res. (2014) 57:16–32. 10.1111/jpi.12140
    1. Sung PH, Chang CL, Tsai TH, Chang LT, Leu S, Chen YL, et al. . Apoptotic adipose-derived mesenchymal stem cell therapy protects against lung and kidney injury in sepsis syndrome caused by cecal ligation puncture in rats. Stem Cell Res Ther. (2013) 4:155. 10.1186/scrt385
    1. Yip HK, Chang YC, Wallace CG, Chang LT, Tsai TH, Chen YL, et al. . Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury. J Pineal Res. (2013) 54:207–21. 10.1111/jpi.12020
    1. Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, et al. . Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med. (2017) 9:eaam7828. 10.1126/scitranslmed.aam7828
    1. Sun CK, Yen CH, Lin YC, Tsai TH, Chang LT, Kao YH, et al. . Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. J Transl Med. (2011) 9:118. 10.1186/1479-5876-9-118
    1. Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. (2009) 58:929–39. 10.1136/gut.2008.168534
    1. Johnson CL, Soeder Y, Dahlke MH. Concise review: mesenchymal stromal cell-based approaches for the treatment of acute respiratory distress and sepsis syndromes. Stem Cells Transl Med. (2017) 6:1141–51. 10.1002/sctm.16-0415
    1. Lu W, Fu C, Song L, Yao Y, Zhang X, Chen Z, et al. . Exposure to supernatants of macrophages that phagocytized dead mesenchymal stem cells improves hypoxic cardiomyocytes survival. Int J Cardiol. (2013) 165:333–40. 10.1016/j.ijcard.2012.03.088
    1. Thum T, Bauersachs J, Poole-Wilson PA, Volk HD, Anker SD. The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol. (2005) 46:1799–802. 10.1016/j.jacc.2005.07.053
    1. Hoogduijn MJ, Verstegen MM, Engela AU, Korevaar SS, Roemeling-van Rhijn M, Merino A, et al. . No evidence for circulating mesenchymal stem cells in patients with organ injury. Stem Cells Dev. (2014) 23:2328–35. 10.1089/scd.2014.0269
    1. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, et al. . Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. (2009) 27:2614–23. 10.1002/stem.187
    1. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. (2014) 32:252–60. 10.1038/nbt.2816
    1. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. (2003) 57:11–20. 10.1046/j.1365-3083.2003.01176.x
    1. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, et al. . Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. (2008) 181:3933–46. 10.4049/jimmunol.181.6.3933
    1. Zhou HP, Yi DH, Yu SQ, Sun GC, Cui Q, Zhu HL, et al. . Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc. (2006) 38:3046–51. 10.1016/j.transproceed.2006.10.002
    1. Hoogduijn MJ, Roemeling-van Rhijn M, Engela AU, Korevaar SS, Mensah FK, Franquesa M, et al. . Mesenchymal stem cells induce an inflammatory response after intravenous infusion. Stem Cells Dev. (2013) 22:2825–35. 10.1089/scd.2013.0193
    1. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, et al. . T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. (2005) 12:47–57. 10.1007/s11373-004-8183-7
    1. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood. (2005) 106:4057–65. 10.1182/blood-2005-03-1004
    1. Zangi L, Margalit R, Reich-Zeliger S, Bachar-Lustig E, Beilhack A, Negrin R, et al. . Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells. (2009) 27:2865–74. 10.1002/stem.217
    1. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. . Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. (2003) 102:3837–44. 10.1182/blood-2003-04-1193
    1. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, et al. . Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol. (2006) 80:267–74. 10.1016/j.yexmp.2005.07.004
    1. Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noel D. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation. (2006) 82:1060–6. 10.1097/01.tp.0000236098.13804.0b
    1. Yu PF, Huang Y, Han YY, Lin LY, Sun WH, Rabson AB, et al. . TNFα-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2(+) neutrophils. Oncogene. (2017) 36:482–90. 10.1038/onc.2016.217
    1. Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, et al. . Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. (2008) 68:4331–9. 10.1158/0008-5472.CAN-08-0943
    1. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, et al. . Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE. (2009) 4:e4992. 10.1371/journal.pone.0004992
    1. Shi Y, Du L, Lin L, Wang Y. Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov. (2017) 16:35–52. 10.1038/nrd.2016.193
    1. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, et al. . Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. (2011) 19:257–72. 10.1016/j.ccr.2011.01.020
    1. Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, et al. . Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun. (2013) 4:1795. 10.1038/ncomms2766
    1. Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C, et al. . CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell. (2012) 11:812–24. 10.1016/j.stem.2012.08.013
    1. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. (2011) 7:651–8. 10.7150/ijbs.7.651

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe